Commission on Cancer Monitoring Compliance

[xrt123]

The COC requires annually a review that patients are being treated, screened or worked up according to a guideline (NCCN, ASCO, etc.) at their centers. Previously we have reviewed whether patients are getting XRT for N2 NSCLC and whether they are referred for XRT for 4+ node positive breast CA. I was wondering if anyone had any good experiences with this and found it helpful. So far we have yet to really use it to aid in changing practice. Any good ideas on what to review?

---

Members don't see this ad.

 

[OTN]

We've done appropriate referral for neoadjuvant chemoRT for rectal cancer before, which was a good one. Easy to get the data, easy-to-follow guidelines, and it can help make sure patients are being referred appropriately.

 

[BobbyHeenan]

We've done make sure XRT starts with cycle 1 or 2 for curative intent limited stage small cell lung. We did identify one med onc that was found to be slow to refer for rad onc (ie initiating first referral after cycle 2).

Other than that I find many of the CoC "studies" or monitoring measures to be a huge hassle and questionably worthwhile.

 

[xrt123]

Thanks. Both good ideas and easy to abstract the info.